Lundbeck presents positive results from migraine drug trial

New data from a study of Lundbeck's migraine drug Vyepti shows a significant effect on patients who have been through two to four prior failed treatments with other types of migraine drugs.

Photo: Jens Dresling

Both primary and secondary endpoints were met in Lundbeck's phase IIIb trial, which goes under the name Deliver, of the migraine drug Vyepti, it reports in a press release on Monday morning.

The study investigated the effect of Vyepti as a treatment for patients with chronic or episodic migraines who have already tried preventive treatments two to four times with other older drugs, which have failed because of a lack of effect or intolerable side effects.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs